Skip to content
TrialScanner

NCT05194124

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Phase 3CompletedRYTMLead

Registry record

Lead sponsor
Rhythm Pharmaceuticals, Inc.
Conditions
Bardet-Biedl Syndrome; POMC Deficiency
Primary completion
Oct 19, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05194124 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05194124: Phase 3 Crossover Trial of... | TrialScanner